Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018158175) COMBINATION OF BUB1 INHIBITORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/158175 International Application No.: PCT/EP2018/054630
Publication Date: 07.09.2018 International Filing Date: 26.02.2018
IPC:
A61K 31/506 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
BAYER PHARMA AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 178 13353 Berlin, DE
Inventors:
SIEMEISTER, Gerhard; DE
BONE, Wilhelm; DE
MENGEL, Anne; DE
Agent:
BIP PATENTS; c/o Bayer Intellectual Property GmbH Alfred-Nobel-Str. 10 40789 Monheim am Rhein, DE
Priority Data:
17158324.828.02.2017EP
17160668.413.03.2017EP
18152574.219.01.2018EP
Title (EN) COMBINATION OF BUB1 INHIBITORS
(FR) COMBINAISON D'INHIBITEURS DE BUB1
Abstract:
(EN) The present invention relates to combinations of at least two components, component A and component B, component A being a Bub1-inhibitor of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same, and component B being an anti-hyperproliferative, cytotoxic and/or cytostatic agent selected from a taxane, such as docetaxel or paclitaxel, or combinations thereof.
(FR) La présente invention concerne des combinaisons d'au moins deux constituants, un constituant A et un constituant B, le constituant A étant un inhibiteur de Bub1 de formule générale (I), ou un stéréoisomère, un tautomère, un N-oxyde, un hydrate, un solvate ou un sel de celui-ci, en particulier un sel pharmaceutiquement acceptable, ou un mélange de ceux-ci, et le constituant B étant un agent anti-hyperprolifératif, cytotoxique et/ou cytostatique sélectionné entre un taxane, tel que le docétaxel ou le paclitaxel, ou des combinaisons de ceux-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)